Mindstrong was founded to solve a hard and meaningful problem:
Measure neurocognitive function unobtrusively, continuously, and remotely to help cure neurodegenerative and neuropsychiatric disorders
We came together as entrepreneurs, technologists, scientists, and physicians to solve that problem.
The Unsolved Problem
Maintaining brain function is the most pressing healthcare and individual mandate in the US. There are 83 million Americans over 50 with silent, progressive cognitive decline and 1 in 3 will die with dementia. Fifteen million Americans live with major depressive disorders that affects their cognitive function. Six million youth are diagnosed with ADHD, one million Americans have Parkinson's disease and will develop Parkinson's dementia, and millions of Americans hold jobs where cognitive impairment puts them or others at risk for injuries.
Like obesity, heart disease, or diabetes, cognitive decline responds to lifestyle and healthcare interventions. But unlike weight, blood pressure, or blood sugar, there is no unobtrusive, ecological biomarker for brain function.
How We Solved It
We developed a novel, patented neurocognitive biomarker tool for capturing cognitive performance unobtrusively, continuously, and ecologically. Our tool passively acquires hundreds of signals from a person's day-to-day interactions with their smartphone. It then transmits the data securely to a HIPAA compliant cloud-computing platform for offline analysis.
In a large, longitudinal study we have shown that data collected and analyzed by our biomarker tool reliably predicts performance on traditional neurocognitive tests of attention, memory, processing speed, language, psychomotor and executive function.
Implication to Clinical Research and Translation
Our novel approach powers remote, realtime, longitudinal monitoring of cognitive and motor performance. For clinical research, it is ecologically valid, as it does not require participants to step outside of a normal routine. The burden on clinical staff is minimal, and the per-participant cost is negligible, enabling massive scaling to a large population. By reducing travel burden through remote monitoring, it broadens the recruitment radius of longitudinal clinical studies and increases provider reach in clinical practice.
By empowering medical research to identify and monitor neurocognitive phenotypes of neurodegenerative disease, our biomarker tool can enable better matching of treatment protocol to disease expression in clinical trials and clinical practice.